Bexagliflozin vs Empagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Bexagliflozin · Brenzavvy

Marketed by Theracos and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT02558296 · Phase 3 · completed

This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison at week 24 was statistically significant in favor of bexagliflozin. HbA1c is an approvable primary endpoint in type 2 diabetes, so the design and the result support strong evidence.

Next expected readout: March 2029 · NCT07547878 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) (met)

Result source: NCT02769481

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01131676 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).

Next expected readout: November 2026 · NCT05057806 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)

Result source: NCT01131676

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBexagliflozinEmpagliflozin
HbA1c, change-0.8% vs -0.4%−0.5 vs placebo20 mg · wk 24 · n 1046NCT02558296
23 other results
  • -1.1% vs -0.6% 20 mg · wk 24 · n 142 · Phase 3 · primary NCT03259789
  • -0.5% vs -0.1% 20 mg · wk 24 · n 138 · Phase 3 · primary NCT02715258
  • -0.6% vs -0.3% 20 mg · wk 24 · n 157 · Phase 3 · primary NCT02836873
  • -0.7% vs -0.8% wk 24 · n 180 · Phase 3 · primary NCT03115112
  • -0.7% vs -0.7% wk 60 · n 193 · Phase 3 · primary NCT02769481
  • -1.1% vs -0.6% 20 mg · wk 24 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs -0.4% 20 mg · wk 24 · n 86 · Phase 3 · secondary NCT02836873
  • -0.6% vs -0.2% 20 mg · wk 24 · n 71 · Phase 3 · secondary NCT02836873
  • -1% vs -0.5% 20 mg · wk 18 · n 158 · Phase 3 · secondary NCT03259789
  • -1.0% vs -0.3% 20 mg · wk 12 · n 158 · Phase 3 · secondary NCT03259789
  • -0.7% vs -0.2% 20 mg · wk 6 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs 0.2% 20 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 65 · Phase 2 · primary NCT02390050
  • -0.6% vs 0.2% 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.1% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
Body weight, change (kg)-3.0 vs -0.4−2.6 vs placebo20 mg · wk 48 · n 922NCT02558296
14 other results
  • -3.6 vs -1.1 20 mg · wk 24 · n 119 · Phase 3 · secondary NCT03259789
  • -1.9 vs -1.1 20 mg · wk 24 · n 128 · Phase 3 · secondary NCT02715258
  • -2.3 vs -0.6 20 mg · wk 24 · n 122 · Phase 3 · secondary NCT02836873
  • -3.4 vs -0.8 wk 24 · n 158 · Phase 3 · secondary NCT03115112
  • -3.7 vs 0.6 wk 60 · n 182 · Phase 3 · secondary NCT02769481
  • -1.9 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.5 vs 0.0 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.7 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.4 vs 0.0 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.6 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -1 vs 0.0 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.7 vs 0 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003
HbA1c below 7%—Not reported34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
Fasting plasma glucose, change-2.5 vs -1.2−1.3 vs placebo20 mg · wk 24 · n 142NCT03259789
10 other results
  • -1.8 vs -1.4 wk 24 · n 180 · Phase 3 · secondary NCT03115112
  • -1.2 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0.1 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.1 vs -0.1 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.2 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.1 vs 0.1 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0.1 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.6 vs -0.1 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
3-point MACE (% with event)—Not reported10.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676

HbA1c, change

Bexagliflozin
-0.8% vs -0.4%−0.5 vs placebo20 mg · wk 24 · n 1046NCT02558296
23 other results
  • -1.1% vs -0.6% 20 mg · wk 24 · n 142 · Phase 3 · primary NCT03259789
  • -0.5% vs -0.1% 20 mg · wk 24 · n 138 · Phase 3 · primary NCT02715258
  • -0.6% vs -0.3% 20 mg · wk 24 · n 157 · Phase 3 · primary NCT02836873
  • -0.7% vs -0.8% wk 24 · n 180 · Phase 3 · primary NCT03115112
  • -0.7% vs -0.7% wk 60 · n 193 · Phase 3 · primary NCT02769481
  • -1.1% vs -0.6% 20 mg · wk 24 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs -0.4% 20 mg · wk 24 · n 86 · Phase 3 · secondary NCT02836873
  • -0.6% vs -0.2% 20 mg · wk 24 · n 71 · Phase 3 · secondary NCT02836873
  • -1% vs -0.5% 20 mg · wk 18 · n 158 · Phase 3 · secondary NCT03259789
  • -1.0% vs -0.3% 20 mg · wk 12 · n 158 · Phase 3 · secondary NCT03259789
  • -0.7% vs -0.2% 20 mg · wk 6 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs 0.2% 20 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 65 · Phase 2 · primary NCT02390050
  • -0.6% vs 0.2% 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.1% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Empagliflozin
-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297

Body weight, change (kg)

Bexagliflozin
-3.0 vs -0.4−2.6 vs placebo20 mg · wk 48 · n 922NCT02558296
14 other results
  • -3.6 vs -1.1 20 mg · wk 24 · n 119 · Phase 3 · secondary NCT03259789
  • -1.9 vs -1.1 20 mg · wk 24 · n 128 · Phase 3 · secondary NCT02715258
  • -2.3 vs -0.6 20 mg · wk 24 · n 122 · Phase 3 · secondary NCT02836873
  • -3.4 vs -0.8 wk 24 · n 158 · Phase 3 · secondary NCT03115112
  • -3.7 vs 0.6 wk 60 · n 182 · Phase 3 · secondary NCT02769481
  • -1.9 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.5 vs 0.0 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.7 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.4 vs 0.0 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.6 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -1 vs 0.0 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.7 vs 0 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Empagliflozin
-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003

HbA1c below 7%

Bexagliflozin
—Not reported
Empagliflozin
34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543

Fasting plasma glucose, change

Bexagliflozin
-2.5 vs -1.2−1.3 vs placebo20 mg · wk 24 · n 142NCT03259789
10 other results
  • -1.8 vs -1.4 wk 24 · n 180 · Phase 3 · secondary NCT03115112
  • -1.2 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0.1 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.1 vs -0.1 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.2 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.1 vs 0.1 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0.1 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.6 vs -0.1 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Empagliflozin
-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297

3-point MACE (% with event)

Bexagliflozin
—Not reported
Empagliflozin
10.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Bexagliflozin: 6 of 6 rows · Empagliflozin: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBexagliflozin
Rows use multiple source trials
Empagliflozin
Rows use multiple source trials
SBP
absolute change · mmHg
-5.03 vs 2.04 placebo mmHg @ 24wk20 mga,b
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
2 other source trials
-4.23 vs -1.9 Sitagliptin mmHg @ 24wk
NCT03115112 · Phase 3
-10.14 vs -7.51 placebo mmHg @ 24wk20 mg
NCT02836873 · Phase 3
-5.56 vs -1.95 placebo mmHg @ 24wk10 mgc,a,b
NCT04233801 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.96 vs -1.95 placebo mmHg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
Seated SBP
absolute change · mmHg
-13.48 vs -6.95 Glimepiride mmHg @ 60wkd,e,f
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.12 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mgc,d,e,f
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
2.63 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Dropout rate
3.9%20 mgg
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
15.5%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.8%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
11.4%20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.3%
NCT03115112 · Phase 3
3.2%20 mg
NCT02836873 · Phase 3
9.2%20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
5.6%10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
6.9%5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
—Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
23.7%10 mgh
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
23.2%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
8%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.7%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
8.7%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
15.9%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
6.2%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
11.2%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
4.4%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
9.4%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
6.1%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
2.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.5%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
18.1%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
10.2%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
7.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5.3%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
7.7%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
8.6%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6.4%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
7.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.8%20 mgg
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
1.4%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.9%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
—20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.6%
NCT03115112 · Phase 3
0.6%20 mg
NCT02836873 · Phase 3
—20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
—Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
11.4%10 mgh
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
11.6%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.9%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
3.2%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.6%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
5.6%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.3%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.1%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
1.7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
2.4%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
0%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.9%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.3%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
—10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
5.9%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
1.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Serious AEs
33%20 mgg
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
11.7%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.9%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.7%20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.7%
NCT03115112 · Phase 3
7%20 mg
NCT02836873 · Phase 3
2.6%20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
4.2%10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
0%Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
0%Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
37.4%10 mgh
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
39%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
4.9%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.2%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
0.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
5.4%10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
0%25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
12.3%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
10.5%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
8.9%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
6.3%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
13.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
9.6%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.7%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0.6%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
1.8%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
3.8%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
2.3%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
0.9%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
3.2%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
20 mgg
hypoglycaemia 42% (placebo 43.4%)
urinary tract infection 11.3% (placebo 10.6%)
upper respiratory tract infection 9.9% (placebo 9.3%)
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
hypoglycemia 16.9%
nasopharyngitis 13.6%
urinary tract infection 11.7%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
20 mg
nasopharyngitis 5.7% (placebo 8.2%)
polydipsia 3.2% (placebo 2.5%)
polyuria 3.2% (placebo 3.8%)
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
20 mg
polyuria 7.2% (placebo 2.9%)
urinary tract infection 5.1% (placebo 2.9%)
abdominal pain 3.6% (placebo 7.2%)
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 7.9%
urinary tract infection 3.7%
hypoglycemia 3.1%
NCT03115112 · Phase 3
20 mg
hypoglycaemia 25.5% (placebo 25.8%)
polyuria 7.6% (placebo 4.5%)
nasopharyngitis 7% (placebo 8.4%)
NCT02836873 · Phase 3
20 mg
hypoglycemia 5.3% (placebo 1.4%)
dysuria 3.9% (placebo 1.4%)
nasopharyngitis 3.9% (placebo 4.2%)
NCT02390050 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 5.6% (placebo 4.2%)
pharyngitis 4.2% (placebo 0%)
arthralgia 2.8% (placebo 0%)
NCT02390050 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 6.9% (placebo 4.2%)
diarrhea 2.8% (placebo 2.8%)
dizziness 2.8% (placebo 1.4%)
NCT02390050 · Phase 2 · registry result, not featured evidence
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 6.3%
gastrointestinal sounds abnormal 6.3%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
laceration 6.3%
presyncope 6.3%
diarrhea 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
dizziness 4.2%
headache 4.2%
nasal congestion 4.2%
NCT02820298 · Phase 1 · registry result, not featured evidence
chest discomfort 4.3%
dizziness 4.3%
headache 4.3%
NCT02820298 · Phase 1 · registry result, not featured evidence
10 mgh
hypoglycaemia 29.6% (placebo 29.4%)
urinary tract infection 14.5% (placebo 14.7%)
hyperglycaemia 9.3% (placebo 18.1%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 37 more results
25 mg
hypoglycaemia 28.7% (placebo 29.4%)
urinary tract infection 14.4% (placebo 14.7%)
nasopharyngitis 9.4% (placebo 9.3%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10mg
hypoglycaemia 15.6% (placebo 9.8%)
urinary tract infection 9.4% (placebo 6.7%)
nasopharyngitis 8% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 5.5% (placebo 4.9%)
urinary tract infection 4.1% (placebo 6.7%)
hyperglycaemia 2.3% (placebo 12.4%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 12.9% (placebo 9.8%)
urinary tract infection 6.9% (placebo 6.7%)
nasopharyngitis 6% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 8.9% (placebo 9.8%)
hyperglycaemia 7.9% (placebo 12.4%)
nasopharyngitis 5% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7% (placebo 4.9%)
upper respiratory tract infections 4.2% (placebo 5.3%)
urinary tract infection 4.2% (placebo 6.7%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7.2% (placebo 4.9%)
urinary tract infection 7.2% (placebo 6.7%)
diarrhoea 5.8% (placebo 0%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
10 mg
headache 16.2% (placebo 15.5%)
hypoglycaemia 16.2% (placebo 12.1%)
vitamin d deficiency 13.5% (placebo 13.8%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
25 mg
hypoglycaemia 17.2% (placebo 12.1%)
blood ketone body increased 10.3% (placebo 3.4%)
headache 10.3% (placebo 15.5%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
10 mg
constipation 10.8% (placebo 4.7%)
pyrexia 6.2% (placebo 4.7%)
nasopharyngitis 4.6% (placebo 6.3%)
NCT04531462 · Phase 4 · registry result, not featured evidence
10 mg
nasopharyngitis 34.9% (placebo 31.1%)
hypoglycaemia 27.9% (placebo 21.1%)
pollakiuria 10.5% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
25 mg
hypoglycaemia 27.8% (placebo 21.1%)
nasopharyngitis 26.7% (placebo 31.1%)
pollakiuria 10% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
10 mg
viral upper respiratory tract infection 31.3%
fall 3.1%
influenza 0%
NCT02589626 · Phase 4 · registry result, not featured evidence
25mg
viral upper respiratory tract infection 33.3%
influenza 9.1%
fall 6.1%
NCT02589626 · Phase 4 · registry result, not featured evidence
10 mg
hypoglycaemia 20.5% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg
hypoglycaemia 15.1% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg-25 mg
lipase increased 7.5% (placebo 3.9%)
cough 6.3% (placebo 1.3%)
upper respiratory tract infection 2.5% (placebo 5.2%)
NCT02182830 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg qd
dyslipidaemia 8.7%
urinary tract infection 7%
upper respiratory tract infection 2.9%
NCT01719003 · Phase 3 · registry result, not featured evidence
25 mg qd
urinary tract infection 7.8%
dyslipidaemia 6.6%
upper respiratory tract infection 4.2%
NCT01719003 · Phase 3 · registry result, not featured evidence
12.5 mg Bid + 1000 mg Bid
diarrhoea 7.5%
dizziness 5.7%
gastritis 5.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 1000 mg Bid
urinary tract infection 10.6%
diarrhoea 7.1%
dyslipidaemia 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 500 mg Bid
urinary tract infection 10%
dizziness 5.3%
diarrhoea 3.5%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 1000 mg Bid
urinary tract infection 7%
dyslipidaemia 4.7%
upper respiratory tract infection 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 500 mg Bid
dyslipidaemia 8.9%
diarrhoea 5.3%
urinary tract infection 5.3%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10 mg
nasopharyngitis 10% (placebo 4.8%)
anal inflammation 0% (placebo 0%)
bartholinitis 0% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
25 mg
anal inflammation 5.3% (placebo 0%)
bartholinitis 5.3% (placebo 0%)
pollakiuria 5.3% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
25 mg
ketosis 19.4% (placebo 3.3%)
fatigue 9.7% (placebo 0%)
headache 9.7% (placebo 10%)
NCT02632747 · Phase 2 · registry result, not featured evidence
10 mg QD
urinary tract infection 6.8% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
25 mg QD
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
12.5 mg BID
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
5 mg BID
urinary tract infection 3.7% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation context differs: age eligibility differs (includes children versus adolescents and adults); baseline_threshold differs (hba1c<=10.5, hba1c>=6.5 versus bmi<=45).
  5. eTreatment context differs: pooled versus monotherapy.
  6. fAssessment timepoints differ: 26 weeks versus 60 weeks.
  7. gPopulation comparability has not been reviewed for 13 of these studies.
  8. hPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bexagliflozin

HbA1c 7.0 or Less 0.14% (n=158) vs 0.03% (n=159) placebo @ 6wk20 mg
event count · % of participants
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
show 6 more results
0.26% (n=158) vs 0.06% (n=159) placebo @ 12wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.26% (n=158) vs 0.1% (n=159) placebo @ 18wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.38% (n=158) vs 0.1% (n=159) placebo @ 24wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
36% (n=75) vs 15.3% (n=72) placebo @ 12wk*20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
22.2% (n=72) vs 15.3% (n=72) placebo @ 12wk*10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
21.1% (n=71) vs 15.3% (n=72) placebo @ 12wk*5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted

Empagliflozin

MACE 3-point Composite 10.4% (n=2345) vs 12.1% (n=2333) placebo10 mg
event count · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
10.5% (n=2342) vs 12.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10.5% (n=4687) vs 12.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
MACE 4-point Composite 12.8% (n=2345) vs 14.3% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
12.8% (n=2342) vs 14.3% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
12.8% (n=4687) vs 14.3% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Silent MI 1.6% (n=1174) vs 1.2% (n=1211) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
1.6% (n=1204) vs 1.2% (n=1211) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
1.6% (n=2378) vs 1.2% (n=1211) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
HF Hospitalization 2.6% (n=2345) vs 4.1% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
2.8% (n=2342) vs 4.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7% (n=4687) vs 4.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Albuminuria 51.5% (n=1403) vs 51.2% (n=1374) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
51.5% (n=1376) vs 51.2% (n=1374) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
51.5% (n=2779) vs 51.2% (n=1374) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Macroalbuminuria 10.9% (n=2037) vs 16.2% (n=2033) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
11.5% (n=2054) vs 16.2% (n=2033) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
11.2% (n=4091) vs 16.2% (n=2033) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Composite Microvascular Outcome 13.9% (n=2057) vs 20.5% (n=2068) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
14.1% (n=2075) vs 20.5% (n=2068) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
14% (n=4132) vs 20.5% (n=2068) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Daily Plasma Glucose Change mg/dL -0.54 vs -0.11 placebo mmol/L @ 24wk10mg
absolute change · mmol/L
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -9.64 mg/dL as posted
show 5 more results
-0.56 vs -0.11 placebo mmol/L @ 24wk*10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -10.01 mg/dL as posted
-0.8 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.36 mg/dL as posted
-1.97 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -35.47 mg/dL as posted
-0.72 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -13.06 mg/dL as posted
-1.63 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -29.34 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk10 mg, 25 mg
responder rate · % of participants
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Time to Treatment Failure 5.5 vs 2.16 placebo months10 mg, 25 mg
time to event · months
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 · converted to months from 167.333 days as posted
Fasting Plasma Glucose Change mg/dL -19.48 vs 15.7 placebo mg @ 26wk10 mg, 25 mg
absolute change · mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 3 more results
-18.45 vs 15.7 placebo mg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-25.61 vs -5.56 placebo mg @ 24wk10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
-29.69 vs -5.56 placebo mg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
Seated DBP 0.78 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mg
absolute change · mmHg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 3 more results
-3.2 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-4.14 vs -2.3 placebo mmHg @ 12wk10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
-5.55 vs -1.3 placebo mmHg @ 24wk10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence

+ 20 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · Empagliflozin's landscape